Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

Abstract Treatment with single agent immune checkpoint inhibitors (ICIs) has tremendously changed second line therapy in NSCLC. However, there are still no reliable biomarkers predicting response and survival in this group of patients. PD-L1 revealed to be a correlating, but no perfect marker. There...

Full description

Bibliographic Details
Main Authors:	Diego Kauffmann-Guerrero, Kathrin Kahnert, Rosemarie Kiefl, Laura Sellmer, Julia Walter, Jürgen Behr, Amanda Tufman
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-05-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-90397-y

Similar Items

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
by: Christiane Bickert, et al.
Published: (2021-06-01)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
by: Saro Kasparian, MD, et al.
Published: (2020-06-01)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
by: Joshua E. Reuss, MD, et al.
Published: (2021-10-01)

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
by: Passiglia F, et al.
Published: (2021-02-01)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
by: Lorenzo Belluomini, et al.
Published: (2019-01-01)

Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
by: Abdo, Mustafa
Published: (2021)

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors
by: Angelo Castello, et al.
Published: (2020-02-01)

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
by: Hidenobu Ishii, et al.
Published: (2020-04-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
by: Taichi Miyawaki, MD, et al.
Published: (2020-06-01)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
by: Xiaohua Li, et al.
Published: (2021-07-01)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
by: Virginia Liberini, et al.
Published: (2021-09-01)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
by: Wei Chong, et al.
Published: (2021-03-01)

Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting
by: Marcus Skribek, et al.
Published: (2020-12-01)

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
by: Angelo Castello, et al.
Published: (2020-05-01)

The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
by: Cristina Vajaitu, et al.
Published: (2018-01-01)

Angiogenesis Inhibitors in NSCLC
by: Anna Manzo, et al.
Published: (2017-09-01)

Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors
by: Davide Brocco, et al.
Published: (2021-02-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
by: Chenxing Zhang, PhD, et al.
Published: (2020-03-01)

Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
by: Yan Chen, et al.
Published: (2020-07-01)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
by: Giustini N, et al.
Published: (2021-03-01)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
by: Min Wang, et al.
Published: (2021-07-01)

Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer
by: Jennifer A. Bridge, et al.
Published: (2018-12-01)

EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER
by: El-Refai, Sherif M.
Published: (2018)

Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
by: Nicola Normanno, et al.
Published: (2019-06-01)

Synthesis of Gallic Acid Analogs as Histamine and Pro-Inflammatory Cytokine Inhibitors for Treatment of Mast Cell-Mediated Allergic Inflammation
by: Xiang Fei, et al.
Published: (2017-05-01)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
by: Filippo G. Dall’Olio, et al.
Published: (2020-10-01)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
by: Wolfgang M. Brueckl, et al.
Published: (2020-12-01)

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
by: Arai, D., et al.
Published: (2022)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
by: Parvin Begum, MBChB.(Hons), et al.
Published: (2021-09-01)

Immune Checkpoint Inhibitors in Advanced NSCLC: [<sup>18</sup>F]FDG PET/CT as a Troubleshooter in Treatment Response
by: Cristina Ferrari, et al.
Published: (2021-09-01)

Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response
by: Maria Kondratova, et al.
Published: (2020-12-01)

Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation
by: Sowmya Ramachandran, et al.
Published: (2021-01-01)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
by: Melissa Lumish, et al.
Published: (2020-06-01)

Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation
by: Jacinth J. Joseph, MD, et al.
Published: (2020-09-01)

Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
by: Fabio Perrotta, et al.
Published: (2019-05-01)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
by: Jing Chen, et al.
Published: (2021-10-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review
by: Gernot Wagner, et al.
Published: (2020-01-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy
by: Shoujian Ji, et al.
Published: (2020-09-01)